Abstract: A compound comprising a tetrahalobenzamidazolebenzene or a bis(tetrahalophenyl)biphenylbisimidazole of the alternative following formulas or dimers thereof wherein each of R1, R2, R3, R4, and R5 are the same or different and are independently selected from the group comprising hydrogen, alkyl, aryl, and halogen.

Abstract: Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a result, these compounds are useful in the treatment of inflammatory and immune cell-mediated diseases.

Abstract: The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably ?-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds.

Abstract: Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

Abstract: The present invention provides an inclusion compound having a cucurbituril derivative of the formula 1 as a host molecule and a metal complex of the formula 2 as a guest molecule. A pharmaceutical composition having an anticancer effect can be obtained by using the inclusion compound according to the present invention. The pharmaceutical composition can prevent effective components from being biologically degraded in vivo and can exhibit continuous drug effect for a long time just by a single dosage by controlling the release time of the platinum complex once it reaches target tumor cells.

Abstract: Provided are novel hetero-polycyclic compounds having a specific structure, color-changing material compositions comprising (A) a fluorescent coloring matter comprising at least one of the hetero-polycyclic compounds described above and (B) a binder material, color-changing films comprising the above hetero-polycyclic compounds, coloring matters comprising the above hetero-polycyclic compounds, and pigments or dyes comprising the hetero-polycyclic compounds described above, and provided are color-changing material compositions which are not deteriorated in a color-changing performance even after used for long time and which are prevented from being unusable due to deposition of coloring matters during storage and color-changing films produced by using the same, and novel hetero-polycyclic compounds, coloring matters and pigments or dyes which actualize them.

Abstract: The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Abstract: The present invention relates to a novel benzimidazole compound represented by formula 1. The novel benzimidazole compound of the present invention is very useful for the production of polymers used as a functional polymer thin film by polymerization with bishydroxy compound. Wherein, X is a halogen such as F, Cl, Br or I, Y is a functional group having strong electron-drawing force such as nitro (—NO2) or trifluoromethyl (—CF3).

Abstract: The invention encompasses novel compounds of Formula I or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain. Methods of treating diseases or conditions mediated by the mPGES-1 enzyme and pharmaceutical compositions are also encompassed.

Abstract: A method and system for storing and evolving hydrogen employ chemical compounds that can be hydrogenated to store hydrogen and dehydrogenated to evolve hydrogen. A catalyst lowers the energy required for storing and evolving hydrogen. The method and system can provide hydrogen for devices that consume hydrogen as fuel.

Abstract: Rylene derivatives of the general formula I in which the variables are each defined as follows: X are joined to one another with formation of a six-membered ring to give a radical of the formula (a), (b) or (c) are both a —COOM radical; are both hydrogen or one of the two radicals is hydrogen and the other radical is halogen or a radical of the formula (d) Y are joined to one another with formation of a six-membered ring to give a radical of the formula (a) when one of the two X radicals is hydrogen and the other X radical is halogen or a radical of the formula (d) or when both X radicals are hydrogen or together are a radical of the formula (a), (b) or (c); are joined to one another with formation of a six-membered ring to give a radical of the formula (b) when one of the two X radicals is hydrogen and the other X radical is halogen or a radical of the formula (d) or when both X radicals are hydrogen or a —COOM radical or together are a radical of the formula (c); are joined to one anot

Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): are useful in providing compounds to assay for such therapeutically useful compounds.

Abstract: An organic electroluminescent material and an organic electroluminescent material used for electroluminescent devices is characterized by emission with a high luminance, high illuminant efficiency, low drive voltage, favorable color purity and high thermal steadiness. The hydrogen atom, halogen atom, cyanide group, alkyl group, alkylidene group, cycloalkane group, alkoxy group, amnio group, aromatic hydroxy group, aromatic bi-alkyl group, alkylaryl group as a substitutive group are used. Not only may it increase the material's glass transition temperature and inhibit the phenomenon of molecular split but also cause this organic electroluminescent device to show a high level of steadiness.

Abstract: There are provided benzimidazolone compounds that provide a plurality of hues from a single structural formula, and are useful as pigments that offer superior dispersibility in binder resins, as well as benzimidazolone compounds that are useful as pigments, and show minimal flocculation when pigments of two or more different hues are blended together to produced a desired hue. A benzimidazolone compound represented by a general formula (1) shown below. (wherein, R1, R2, R3 and R4 each represent, independently, a hydrogen atom, an alkyl group of 1 to 5 carbon atoms, or an alkoxy group of 1 to 5 carbon atoms, and R5 and R6 each represent, independently, an alkyl group of 1 to 5 carbon atoms).

Abstract: Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed.

Abstract: A dye composition comprising at least one mixed dye comprising at least two chromophore chosen from azine and (hetero)aromatic nitro compounds, optionally associated with at least one chromophore chosen from methine and carbonyl compounds; a process for dyeing keratin fibers, for example, human keratin fibers, such as the hair, using the composition, a multi-compartment device comprising the composition; and the abovementioned mixed dyes.

Abstract: Disclosed herein are a dye composition comprising at least one mixed dye comprising at least one chromophore chosen from chromophores of the azo family and the tri(hetero)arylmethane family; and the mixed dyes. Further disclosed herein are a process for dyeing keratin fibers, such as human keratin fibers, using the composition, and a device comprising the composition.

Abstract: The present invention relates to a dye composition including at least one mixed dye containing at least one chromophore of methine or carbonyl type or their combinations. The invention furthermore relates to a process for dyeing keratin fibers, especially human keratin fibers, such as the hair, using the composition, and also to a suitable kit. The invention also relates to the abovementioned mixed dyes per se.

Abstract: Compounds of the formula (I) in which R1, R2, R3 and R4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, pre-menstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence. Strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

Abstract: The invention relates to compounds of the general formula wherein R1, R2, R3, R4, R5, R6, R7, X, Y and a have the significances given in the patent, and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded animals.

Abstract: Optically anisotropic films based on sulfoderivatives of 1,8-naphthoylene-1?,2?-benzimidazole are disclosed. These compounds form stable lyotropic liquid crystal systems that exhibit excellent optical properties with films that are significantly thinner that the current state of the art. The lyotropic liquid crystal systems may be deposited on substrates for use in a wide variety of commercial applications.

Abstract: Disclosed are compositions comprising at least one [benzo[4,5]imidazo(heterocycle)] compound, said [benzo[4,5]imidazo(heterocycle)] compound selected from the group consisting of structures I and II, wherein R1 and R2 are independently selected from the group consisting of a hydrogen atom, electron withdrawing group, organic group, divalent 1,2-cycloalkylidene group, or combinations thereof; “q” is independently an integer from 1–4, L is a linking group, and “r” is independently 0 or 1; said at least one [benzo[4,5]imidazo(heterocycle)] compound being present at a concentration sufficient to cause said composition to exhibit upon exposure to an excitation radiation having a wavelength of from about 330 nanometers to about 390 nanometers, a maximum fluorescence emission wavelength of greater than or equal to about 470 nanometers; and a Stokes shift of greater than or equal to about 80 nanometers; wherein the wavelengths are measured in bisphenol A polycarbonate matrix.

Abstract: The invention relates to a dye composition comprising a direct dye consisting of different chromophores, the dye having a particular L*a*b* value. The invention also relates to the dyeing process using this composition and to the use of this composition for dyeing keratin fibers. These compositions in particular make it possible to obtain particularly fast colorations.

Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.

Abstract: The present invention relates to a lightening dye composition comprising, in a suitable dyeing medium, an oxidizing agent, an alkaline agent in an amount such that the pH of the composition is greater than 7, and a mixed cationic dye comprising several chromophores linked together via a linker, at least two of the chromophores being different, the chromophores having an absorbance of between 400 and 800 nm. The invention makes it possible to obtain particularly fast colorations.

Abstract: The present invention relates to 1,3-diaza-dibenzoazulene derivatives, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumor necrosis factor-? (TNF-?) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

Abstract: Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring of a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; pi represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different.

Abstract: Sulfoderivatives of perylenetetracarboxylic acid dibenzimidazole are provided. These compounds form liquid crystal systems possessing high quality optical properties. The resulting liquid crystal systems are readily applicable onto a substrate to obtain optically isotropic or anisotropic, at least partially crystalline films applicable in various fields.

Abstract: A compound represented by formula (IA) or (IIA): wherein R11, R12 and R13 each represents a hydrogen atom, an aliphatic hydrocarbon group, an aryl group or a heterocyclic group; L1 represents a connecting group; R11 and R12, R11 and L1 and R12 and L1 may each combine with each other to form a ring when possible; R14, R15, R16 and R17 each represents a hydrogen atom or a substituent; and R13 to R17 may each combine with each of R11 to R17 or L1 to form a ring when possible; wherein R13 to R17 and L1 have the same meaning as in formula (IA); Q represents an atomic group necessary for forming a 5-, 6- or 7-membered ring with N; and R13, R14, R15, R16 and R17 may each combine with each of R13 to R17, the connecting group L1 or the atomic group Q to form a ring.

Abstract: A cocatalyst or cocatalyst component, including a compound corresponding to the formula: (A*+a)b(Z*J*j)?cd, wherein: A* is a cation of from 1 to 80 atoms, not counting hydrogen atoms, Z* is an anion group of from 1 to 50 atoms, not counting hydrogen atoms, containing two or more Lewis base sites; J* is a Lewis acid of from 1 to 80, not counting hydrogen atoms, coordinated to at least one Lewis base site, and optionally two or more such J* groups may be joined together in a moiety having multiple Lewis acidic functionality, j is from 2 to 12 and a, b, c, and d are integers from 1 to 3, with the proviso that a×b is equal to c×d, and provided further that one or more of A*, Z* or J* comprises a hydroxyl group or a polar group containing quiescent reactive functionality.

Abstract: The invention provides organic compounds of the general structure (1) 1

Abstract: Disclosed herein are bridged perinones/quinophthalones of the general formula (I) or tautomeric forms thereof where X1, X2, Ar1 Ar2 and B are as described herein and are particularly characterized in that the bridging B is a radical of the formula —T1—W—T2—, where T1 and T2 are independently O or S and W is alkylene, especially C1-C6-alkylene, C6-C10-arylene, especially phenylene or cycloalkylene, which are each optionally substituted or is the radical of the formula (a) where the phenyl rings are optionally substituted and A is a radical of the formula O, S, SO, SO2 or CO, optionally substituted alkylene, or optionally substituted cycloalkylene, said alkylene or cycloalkylene being attached to the adjacent phenyl rings itself or else via its substitutents, or W is a radical of the formulae where s and t are independently from 1 to 6, the ends of the radical B each being attached to an aromatic carbon atom of the two radicals Ar1

Abstract: The present invention is an organic light emitting device (OLED) comprising an anode, a cathode and a luminescent region provided between the anode and the cathode. The luminescent region comprises an electron injection and transporting zone and at least one of a hole injection and transporting zone and a mixed charge transport layer. One or both of the electron injection and transporting zone and the mixed charge transporting layer comprises an azole compound represented by formula I and/or II. The provision of the novel azole compounds of the invention as electron transport materials within an organic electroluminescent device advantageously reduces power consumption and increases power conversion efficiency within the device and as such, are suitable for a variety of display applications.

Abstract: The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of the following general formulas that inhibit topoisomerase I activity.

Abstract: There are provided novel chemical compounds and their uses in the preparation of polymers and oligomers, and the preparation of such compounds. In certain embodiments there are provided dendritic polymers and oligomers, of a type having at least four polymeric or oligomeric organic chains emanating from a single chemical core, each of the chains being of substantially equal length and substantially the same chemical composition. Such compounds may be referred to as dendrimers. Also provided are novel chemical entities useful as core entities in the preparation of dentrimers. Dendrimers can recognize a core substructure to which the polymeric/oligomeric chains (“dendrons”) are covalenty attached and from which they extend with systematic branching radially outward in a three dimensional fashion, to approximately the same extent to each other. Together, core and dendrons constitute macromolecules possessing a high degree of internal structural replication attributable to the branches.

Abstract: Imido and amido substituted acylhydroxamic acids which reduce the levels of TNF&agr; and inhibit phosphodiesterase in a mammal. A typical embodiment is (3-(1,3-dioxoisoindolin-2-yl)-3-(3-ethoxy-4-methoxyphenyl)propanoylamino)propanoate.

Abstract: A composition comprising: (a) from 0.1% to 20% of at least one compound comprising: (i) a five-, six-, or seven-membered ring containing a thiourea functional group; and (ii) at least one of (A) a carbocyclic ring system fused to the five-, six-, or seven-membered ring; and (B) an aryl, aralkyl, C4-C22 alkyl or C4-C22 alkenyl group attached to a ring carbon atom of the five-, six-, or seven-membered ring; and (b) a lubricating oil.

Abstract: Disclosed is a compound represented by the following formula (I): wherein Z1 represents an atomic group necessary to form a 5- or 6-membered nitrogen-containing heterocyclic ring; Z2 represents an atomic group necessary to form a 5- or 6-membered heterocyclic ring, Z2 may further be substituted, or may be condensed with a hetero ring or a benzene ring; R1 represents a hydrogen atom, a halogen atom, a mercapto group, an alkyl group, an alkenyl group, an aryl group, an alkylthio group, an alkenylthio group, or an arylthio group; L1 and L2 each represents a methine group; p1 represents 0 or 1; V1 represents a substituent; and n represents 0, 1 or 2, and when n represents 2, a plurality of V1 may be the same or different.

Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.

Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.

Abstract: This invention relates to compounds represented by the general formula [I]   wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

Abstract: Compounds of the formula (I): wherein A, Y, R, X, R1, R2, R3 and R4 are as defined above are inhibitors of rotamase enzymes in particular FKBP-12 and FKBP-52. The compounds therefore moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases or other disorders involving nerve damage.

Abstract: A composition comprising (a) an effective amount of a guest chromophore embedded in a matrix of a host chromophore, or (b) a host chromophore and an effective amount of a guest chromophore both embedded in a polymer matrix, wherein the absorption spectrum of the guest chromophore overlaps with the fluorescence emission spectrum of the host chromophore, and wherein the host chromophore is selected from the group consisting of benzo [4,5]imidazo[2,1-a]isoindol-11-ones.

Abstract: A composition comprising (a) an effective amount of a guest chromophore embedded in a matrix of a host chromophore, or (b) a host chromophore and an effective amount of a guest chromophore both embedded in a polymer matrix, wherein the absorption spectrum of the guest chromophore overlaps with the fluorescence emission spectrum of the host chromophore, and wherein the host chromophore is selected from the group consisting of benzo [4,5]imidazo [2,1 -a]isoindol-11-ones.

Abstract: Compounds with heterocyclic-hydroxyimino-fluorene nuclei that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Abstract: The present invention is directed to nitrosated or nitrosylated &agr;-adrenergic receptor antagonists, compositions comprising &agr;-adrenergic receptor antagonists that are optionally substituted with at least one NO or NO2 moiety and compounds that donate, transfer or release nitric oxide or elevate levels of endogenous endothelium-derived relaxing factor, and methods for treating sexual dysfunctions in males and females.

Abstract: A description is given of diphenyl compounds of formula wherein R is a camphor or hydantoin derivative; and R1 is hydrogen; or C1-C5alkyl. These compounds are suitable as light stabilizers in cosmetic, pharmaceutical and veterinary formulations.

Abstract: Compounds with heterocyclic-hydroxyimino-fluorene nuclei that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Abstract: Novel granulatimide compounds and pharmaceutical formulations thereof are provided.

Abstract: A nitrogen-containing tetracyclic compound represented by the formula: wherein Y1—Y2—Y3 is N—C═N or a group represented by the formula: C═C—NR3 (wherein R3 is a hydrogen atom, a C1-5 alkyl group or a nitrogen-containing C2-10 alkyl group), Y4 is S, SO, SO2, CH2 or a group represented by the formula: NR4 (wherein R4 is a C1-5 alkanoyl group or a C1-5 alkyl group), R1 and R2 are the same or different, and are each a hydrogen atom, a C1-10 alkyl group, a C3-15 alkoxyalkyl group or a C3-15 alkylaminoalkyl group, or R1 and R2 taken together with the nitrogen atom to which they are attached form a cyclic amino group, X1 and X2 are the same or different, and are each a hydrogen atom, a C1-5 alkyl group, a C1-5 alkoxy group or a halogen atom, and n is 0, 1 or 2; or a pharmaceutically acceptable salt thereof.